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GENERAL INTRODUCTION 
Amyloid Beta Protein 
Alzheimer's disease is characterized by extracellular lesions known as 
senile plaques and intracellular lesions known as neurofibrillary tanglessi. Both 
are localized to discrete regions of the brain such as the cerebral cortex, 
hippocampus, and amygdala74. Senile plaques and neurofibrillary tangles contain 
a 4.2 kd peptide known as amyloid beta protein (pAP or pA4)26,27. The source of 
this peptide is unknown, although a variety of cell types are capable of producing 
much larger precursor proteins24,62,64. These precursor proteins are collectively 
known as beta amyloid precursor protein (pAPP). pAPPs are naturally occurring, 
highly abundant64, membrane-spanning proteinsi?. Although a great deal has 
been learned about pAPPs, their actual functions have not been determined. 
By unknown means, pAPP is cleaved to pAP which then aggregates to 
form a highly insoluble, beta-pleated sheet that accumulates in tangle-bearing 
neurons and senile plaques. Until recently pAP was thought to be an inert bi-
product of the disease. Yankner and colleaguesa4, however, have demonstrated 
that a synthetic peptide homologous to the first 40 amino acids of pAP (pi -40) has 
both neurotrophic and neurotoxic effects on cultured neurons84. These effects 
were dependent on both the age of the peptideeo.ei and the maturity of the 
cultures84. For example, freshly prepared pAP fragments were toxic to 
differentiated neurons, (neuronal precursors that are present for 2-3 days84) and 
trophic to undifferentiated neurons, (cells that elaborate processes and have 
characteristics typical of mature neurons76,77,84). However, when pAP was aged 
(i.e., incubated 2-4 days at 37°C) prior to exposure, it was toxic to undifferentiated 
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neurons as welieo.ei. pike and colleagueseo.ei contend that the degree of peptide 
aggregation dictates the level of toxicity. 
Yankner and colleagues42,84 have also suggested that pAP shares 
sequence homology with substance P and acts via the substance P receptor. In 
both in vivo and in vitro studies, substance P blocked amyloid-induced cell death 
and amyloid-induced immunoreactivity to characteristic Alzheimer's antigens42,e4. 
Unfortunately, these studies have yet to be fully replicated by independent 
laboratories and are controversial. In preliminary work, I found that substance P 
antagonists were toxic to differentiated hippocampal cultures and that this toxicity 
could be reversed by treatment with substance P. In addition, I observed a 
trophic response to pi-40 by undifferentiated cells and a toxic response by 
differentiated cells. Substance P, however, did not significantly reverse either 
effect. 
Aluminum 
Aluminum is a biologically active metal that has diverse effects on many 
organs of the body5,23,65,87,88. in the brain, it appears that once aluminum gains 
entry, it accumulates in neurons. Perhaps the best example of aluminum toxicity 
in the human brain has been observed in chronic renal dialysis patients. It was 
discovered that dementia associated with dialysis encephalopathy syndrome 
(DES) frequently occurred as a result of aluminum contaminants in the dialysate 
water and the administration of an aluminum phosphate buffer78,79. Interestingly, 
aluminum is co-localized in plaquesis and tangles54-56 in both Alzheimer's and 
Down's syndromeie. 
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Cytoskeletal proteins have been the focus of several studies because they 
are frequently disrupted in neurodegenerative diseases such as Alzheimer's. For 
example, epitopes for MAP-2 and tau have been found in the neurofibrillary 
tangles (NFTs) of the tangle-bearing neurons seen in Alzheimer's diseases,12,22,38. 
41,71,81,86. These proteins seem to abnormally accumulate in NFTs. Because the 
degradation34 and transport of some cytoskeletal proteins to their appropriate 
neuronal compartments (i.e. soma, dendrite or axon) is dependent on their 
phosphorylation states52, abnormal phosphorylation might result in a build up of 
these proteins within the soma. Aluminum escalates levels of cyclic adenosine 
monophosphate (cAMP)33. Increased cAMP could result, directly or indirectly in 
the altered phosphorylation and/or altered degradation of many cytoskeletal 
proteins. Further, aluminum induces the aggregation of highly phosphorylated 
cytoskeletal proteins in vitrons. Thus, in disease states, aluminum has the potential 
to cause abnormal accumulation of cytoskeletal proteins. In support of this 
hypothesis, cultured rat neurons43 or NB2a/dl neuroblastoma cellsee exposed to 
aluminum develope neurofilamentous inclusions. Similarly, accumulation of 
neurofilaments73,8o and a dying back of the dendritic treesa has been observed in 
susceptible neurons of rabbits given aluminum centrally. 
Although aluminum may contribute to the accumulation of cytoskeletal 
proteins in NFTs, recent evidence has suggested that in normal neurons, 
aluminum may actually cause a decease in expression. Johnson and 
colleagues34 reported that adult rats chronically exposed to aluminum have 
decreased l\/IAP-2 and spectrin levels within the hippocampus. These effects may 
be due to decreased expression rather than increased degradation34. |n support 
of this theory, when rabbits were treated with aluminum, they had decreased 
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mRNA levels for alpha-tubulinso and the 68 kDa neurofilament subunltso.sa. 
Interestingly, a similar finding has also been reported for the mRNA levels of 
tubulinio and the 68 kDa neurofilament subunit from the Alzheimer's cortexio.48. 
Because aluminum is known to bind directly to DNA75 and increase cAMP levelsss, 
transcription may be blocked as a result of altered promoter phosphorylation or 
direct interference with the DNA coding for cytoskeletal proteins. In addition, 
Lukiw and colleagues44 have shown that aluminum enhances the stability of linker 
histone-DNA complexes, potentially blocking DNA transcription. 
Because the aluminum ion does not appear to be capable of crossing the 
blood brain barrier, it seems likely that a carrier protein such as transferrin may be 
involvedea. In support of this conjecture, transferrin is the sole plasma binding 
protein for aluminum in chronic renal dialysis patientsn. While the distribution of 
transferrin receptors in the brain is said to have a peptide-like distribution, this 
distribution does not correlate well with areas high in ironie,29. iron-rich regions, 
however, frequently receive projections from neurons that do have high densities 
of transferrin receptorsas. It has been postulated that iron may be transported 
down the axon to secondary neuronsis.aa. The situation for aluminum, on the 
other hand, seems quite different. In patients suffering from DES, aluminum 
deposition occurs primarily in brain regions with high densities of transferrin 
receptors49. These studies imply that iron and aluminum have similar 
mechanisms of transport to the neuron via the transferrin receptor, but the 
similarities end once the metal is taken up by the neuron. Iron may be 
transported down the axon to secondary neurons, while aluminum appears to 
accumulates within the first neuron. 
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Purpose of the Research in this Dissertation 
The intent of this dissertation worl< was to characterize effects of aluminum 
and amyloid on primary cultures of hippocampal neurons. Both amyloid and 
aluminum have been implicated in neurodegenerative diseases such as 
Alzheimer's and Down's Syndrome. Because previous culture work with these 
compounds has been complicated by their insolubility in physiological solutions, I 
sought to develop novel testing procedures. As such, my approach was to find 
alternative methods for exposing cultured neurons. These methods should be 
similar to the exposure that neurons receive in vivo. For example, past culture 
studies, including my own, have examined effects on cells exposed to aluminum 
ions. However, it is very unlikely that aluminum is transported to the brain as a 
free lone?. Instead, aluminum in vivo is complexed to transferrin^. Accordingly, in 
Chapter 1 of this dissertation I used transferrin to mediate the delivery of 
aluminum to neurons. 
Likewise I sought to find a more natural and usable method for the 
exposure of neurons to amyloid in culture. In both Alzheimer's and Down's 
syndrome, amyloid is concentrated at the center of focal neuritic degenerations 
called neuritic plaquesia. The amyloid in these neuritic plaques is described as 
aggregated and highly insolubleis. Therefore, based on the morphological 
relationship between neurons and plaques and the insolubility of amyloid, it is 
likely that neurons are exposed to amyloid by direct contact with the plaques. In 
my cultures, I attempted to mimic this environment by exposing neurons to aged 
amyloid coated on the culture surface. With this system, because my neurons 
were maintained in direct contact with amyloid, I feel that amyloid was effectively 
tested in Chapters 2 and 3. The information gained from these studies may aid in 
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unraveling the contributions of amyloid and aluminum in neurodegenerative 
diseases such as Alzheimer's. 
Explanation of Dissertation Format 
This dissertation was prepared in accordance with the Iowa State 
University Graduate College Thesis Manual for the inclusion of papers in a thesis. 
Following the Dedication, Table of Contents and General Introduction, three 
papers are presented. Each of these papers are currently being submitted for 
publication to journals in the field of neuroscience. After Paper III, a General 
Summary and a General Discussion address the findings of all three papers. The 
bibliography that follows applies only to references that were used in the General 
Introduction, General Summary and General Discussion. 
7 
PAPER I. EFFECTS OF TRANSFERRIN AND ALUMINUM ON DISPERSED 
HIPPOCAMPAL CULTURES 
8 
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SUMMARY 
The trivalent metal, aluminum, is neurotoxic and its presence in dyalysis 
encephalopathy syndrome (DES), Parkinsonian dimentia of Guam and 
Alzheimer's disease has been documented. To date, however, the mechanism of 
aluminum uptake by the brain and ultimately neurons remains unknown. Because 
the aluminum ion does not appear to be capable of crossing the blood brain 
barrier, it seems likely that a carrier protein such as transferrin may be involved. 
In support, aluminum deposition in DES is reported to be highest in brain regions 
containing high densities of transferrin receptor. In the present study, the role of 
transferrin as a carrier for aluminum was examined. Hippocampal cultures were 
exposed to transferrin loaded with aluminum (TF-AL) and analyzed for changes in 
viability and neurite outgrowth. We report that TF-AL exerted effects that were 
dependent upon the age of the cultures. TF-AL was highly neurotoxic to Day 0 
neurons exposed for 24 h, but did not significantly affect the survival of Day 4 
neurons exposed for 72 h. These neurons, instead, had reduced MAP-2 and tau 
immunoreactive process lengths. The findings of this study support the theory 
that transferrin delivers aluminum to neurons, influencing neuritic behavior and 
survival. 
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INTRODUCTION 
Aluminum is known to be associated with several neurodegenerative 
diseases, but perhaps the best example of aluminum neurotoxicity in humans is 
dialysis encephalopathy syndrome (DES). This disease is known to occur in 
patients undergoing dialysis due to chronic renal failure4. Ultimately, it was 
determined that this dementia is linked to aluminum contaminants in the dialysate 
water and the administration of an aluminum phosphate buffer resulting in high 
levels of aluminum in the brain35,64,65. Removal of aluminum contamination from 
the dialysis waters and chelation treatmenti.sa have been effective in preventing or 
reversing the effects of DES. 
Amyotrophic lateral sclerosis and Parkinsonian dementia of Guam are 
other diseases that have strong ties to aluminum. Perl and colleagues44, using 
scanning electron microscopy with energy-dispersive x-ray spectrometry, reported 
that afflicted patients had prominent accumulations of aluminum in the 
cytoplasmic and nuclear regions of hippocampal neurons containing neurofibrillary 
tangles. Other studies have also found significant aluminum levels in the brains of 
patients with Parkinsonian dimentia of Guam2o.45,49. it has been suggested dietary 
aluminum plays key a role in the occurance of these diseasesis.so. 
Aluminum has also been implicated in other neurodegenerative diseases 
such as Alzheimer's and Down's syndrome. Several epidemiological studies have 
demonstrated a positive correlation between aluminum levels in drinking water 
and the incidence of senile dementiai8,32. Although it now seems unlikely that 
aluminum plays a causal role, a number of studies have indicated that aluminum 
is localized in both the neuritic plaquesa.i? and the tangles43,46,47 of Alzheimer's 
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and Down's syndromeie. In contrast, a recent study by Landsberg and 
colleagues29 did not find aluminum in Alzheimer's plaques. Using state of the art 
nuclear microscopy and fresh Alzheimer's tissue, their results suggested that 
previous studies were flawed due to aluminum contaminants in staining reagents. 
It should be mentioned, however, that Landsberg and colleagues did not examine 
aluminum in tangles or other regions of the brain. A previous study by Stern and 
colleagues57 using laser microprobe mass analysis, similarly did not find aluminum 
in plaques, but did consistently detect it in tangles. So although there is some 
question as to whether aluminum exits in plaques, reports of aluminum in tangles 
and other areas of the Alzheimer's brain warrant further investigation. 
Using animal and tissue culture models, several groups have sought to 
determine aluminum's effects on biological systems. The evidence from these 
studies strongly suggest that aluminum alters neurite outgrowth and disrupts 
cytoskeletal proteins. For example, an accumulation of neurofilamentseo.se.e? and 
a dying back of neuronal dendritic trees48 were observed in rabbits administered 
aluminum centrally. In addition, when Johnson and colleaguesze exposed rats to 
dietary aluminum for long periods there was a marked region specific reduction of 
the microtubule associated protein, MAP-2. Similarly, culture studies have 
suggested that aluminum alters neurite outgrowth and disrupts the cytoskeleton. 
Rat neurons3o and NB2a/dl neuroblastoma cells54 exposed to aluminum develop 
irregular neurofilamentous inclusions. Further, Uemura and colleaguesei.ez 
recently demonstrated that aluminum can induce unusual neurite sprouting and 
morphological changes in cultured neuroblastoma cells and hippocampal 
neurons. 
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Although aluminum neurotoxicity has been fairly well documented, the 
mechanism of aluminum uptake by the brain remains unclear. Because it is 
unlikely that aluminum can exist at physiological pH as a free ionss, it is probable 
that a carrier protein such as transferrin is involved. In support of this theory, Shi 
and Haugss demonstrated that transferrin promotes aluminum uptake in vitro. At 
physiological pH, aluminum uptake by neuroblastoma cells occured when 
aluminum was bound to transferrin. 
The present study examined effects of transferrin and aluminum (TF-AL) 
on the survival and growth of cultured hippocampal neurons. Our findings 
indicate that transferrin delivers aluminum to hippocampal neurons, resulting in 
age-dependent neurotoxicity and changes in neurite outgrowth. This study 
supports the theory that aluminum neurotoxicity involves transferrin as a carrier. 
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MATERIAL AND METHODS 
Culturing of Hippocampal Neurons 
Hippocampal neurons isolated from El 8 rat fetuses (Holtzman) were 
dispersed and frozen in IVIEM-alpha (IVIEM, Gibco) containing 10% fetal bovine 
serum (FBS), Gentamicin (Gibco), and 8% DMSO (Sigma)33.34. One day prior to 
plating, 24 well culture plates (Costar) were polylysine coated and incubated 
overnight with MEM supplemented with Gentamicin and 10% FBS. 
Cryopreserved neurons were then rapidly thawed in a 37°C water bath and 
plated. After 1 h the cells were washed with MEM and the medium was replaced 
with either MEM supplemented with 10% NuSerum (Collaborative Research) or 
MEM supplemented with MN2 (progesterone, insulin, sodium selenite, and 
transferrin). MN2 is a modified version of Bottenstein and Sato's N2 defined 
media supplements that has rat transferrin substituted for human transferrin. 
Chelation of Aluminum to Transferrin 
To eliminate the possibility of contaminating metals when complexing 
transferrin and aluminum (TF-AL), rat apotransferrin (Sigma) was incubated with 
Chelex resin (Biorad) for 1 h at pH 5.5 (27° C). The resin was then separated 
from the transferrin solution by filtration through a low protein binding filter 
(Millipore). A 5 times concentration of aluminum potassium sulfate was then 
added and the pH was slowly raised to 8.3 using 1 M sodium bicarbonate. The 
solution was again incubated with Chelex beads (1 h, pH 8.3) followed by 
passage through a 10,000 MW low protein binding filter (Millipore) and 
resuspension in culture medium. Apotransferrin (ATF) was prepared in the same 
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manner as TF-AL with the exception that aluminum potassium sulfate was 
omitted. The transferrin concentration was determined for each sample using the 
Bradford protein assay; with bovine serum albumin as the standard. Difference 
spectroscopy was used to verify the chelation and characteristic peaks were 
observed for the transferrin complexessa. 
Exposure of Hippocampal Cultures 
To test for effects of transferrin (TF) and aluminum (AL) on day 0 
hippocampal cultures at 1 h post plating, neurons were placed in defined medium 
containing either ATF (0.75, 1.5, 3.0, or 6.0 [aM), non-complexed AL and TF 
(ATF+AL; 1.5, 3.0, 6.0 or 12.0 for AL) or AL chelated to transferrin (TF-AL; 
0.75, 1.5, 3.0, or 6.0 jaM). Twice the concentration of free AL was used because 1 
mole of TF is capable of binding 2 moles of ALio. The exposed cells were then 
allowed to grow unperturbed for 24 h (37°C, 5% C02/95% room air). At that time 
the surviving neurons were counted and fixed for histochemical analysis of AL or 
immunohistochemistry. To test for effects of TF and AL on 4 day hippocampal 
cultures, the neurons were grown in MEM plus 10% NuSerum for 4 days prior to 
exposure as described above. After 72 h the cultures were counted and fixed. 
Microtubule Associated Protein Immunohistochemistry 
At the specified times, cultures were fixed in cold 0.1 M PBS containing 4% 
paraformaldehyde (10 min). They were then washed with 0.05 M tris buffered 
saline, incubated in 0.02% triton-X 100 (5 min, 27°C), and blocked in 1% BSA and 
1.5% normal horse serum (30 min, 37°C). Following overnight incubation (4°C) 
with the tau-1 antibody (1:2000, Boehringer Mannheim) or MAP-2 antibody 
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(1:2000, Sigma), visualization was accomplished using rat-preabsorbed 
biotinylated horse anti-mouse IgG (Vector; 45 min, 27°C) and horseradish 
peroxidase (HRP nickel enhanced DAB method; Elite Kit, Vector). The HRP 
reaction was halted at 6 min by immersion in cold normal saline. The cells were 
coverslipped using Glycergel (DAKO) and examined by phase and light 
microscopy. 
Histochemical Analysis of Aluminum 
At 3 or 24 h post exposure, cultures were fixed with 95% ethanol/5% acetic 
acid (20 min, -20°C), followed by treatment with 1.0% HCI (10 min, 27°C). They 
were then washed with deionized water and exposed to a solution of 0.2% morin, 
0.5% acetic acid and 85% ethanol (10 min, 27°C). After further washing, the 
cultures were coverslipped using Glycergel and examined by fluorescence 
microscopy. 
Morphometric Analysis of Neurite Outgrowth 
Four fields per well were selected using a fixed predetermined pattern. 
From these fields, images were captured on a Macintosh II ci equipped with a 
Data Translation capture board. Quantification was performed using NIH Image 
(courtesy of Wayne Rasband, National Institute of Health). For MAP-2 and tau, 
the lengths of immunoreactive processes were measured by performing a density 
slice and converting to a binary image. This image was then eroded to the level 
of a single pixel wide line drawing. The soma was removed and the lengths of the 
remaining neurites were determined by measuring the perimeter divided by two. 
Process lengths were totaled for each cell and averages were obtained for each 
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experiment. All experiments were performed in triplicate. The t-test was used to 
analyze differences between groups and a p-value less than 0.05 was accepted 
as statistically significant. 
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RESULTS 
Viability of Cells 
Hippocampal cultures were exposed to ATF+AL (1.5, 3.0, 6.0 or 12.0 nM) 
or TF-AL (0.75, 1.5, 3.0, or 6.0 jaM) on both Day 0 and Day 4. With the exception 
of 0.75 nM TF-AL (t=0.45, df=22, p=0.658), the survival of Day 0 neurons 
exposed to TF-AL for 24 h was significantly reduced at all of the concentrations 
tested (Figs. 1A and 2; 1.5 [aM, t=2.22; p=0.037; 3.0 nM; t=21.34, p<0.0001; 6.0 
[iM, t=18.15, p<0.0001; df=22 for all conditions). In contrast, ATF+AL had no 
effect on the survival of hippocampal neurons, regardless of the concentration 
(Figs. IB and 2; 1.5 (xM, t=1.35, p=0.191; 3.0 [aM, t=-1.12, p=0.275: 6.0 [aM, 
t=0.48, p=0.636: 12.0 [aM, t=-1.35, p=0.19: df=22 for all conditions). The viability 
of Day 4 neurons following a 72 h exposure was quite different from that of Day 0 
neurons following a 24 h exposure. Even at the highest concentration tested, TF-
AL did not significantly affect Day 4 neuronal survival compared to control (Fig. 3; 
0.75 jaM, t=1.16, p=0.257: 1.5 jaM, t=0.84, p=0.413: 3.0 ^aM, t=0.44, p=0.664: 6.0 
jaM, t=0.34, p=0.74; df=22 for all conditions). Similarlly, ATF+AL was not toxic 
compared to control (Fig. 3; 1.5 ^M, t=-0.76, p=0.454: 3.0 ^M, t=0.09, p=0.928; 
6.0 [aM, t=-0.47, p=0.643: 12.0 |aM, t=-0.14, p=0.89: df=22 for all conditions). 
Neurite Outgrowth 
Day 4 neurons were exposed to either ATF+AL or TF-AL. After 72 h the 
cultures were processed for MAP-2 and tau immunohistochemistry and the 
lengths of MAP-2 and tau immunoreactive (IR) processes were measured. 
Neurons exposed to TF-AL had MAP-2 IR processes that were significantly 
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reduced for all of the concentration above 0.75 [aM (Figs. 4A, 4B and 5; 0.75 [aM, 
t=-0.44, p=0.662: 1.5 [aM, t=5.14, p<0.0001: 3.0 jaM, t=11.14, p<0.0001; 6.0 jaM, 
t=10.98, p<0.0001; df=22 for all conditions). ATF+AL did not significantly affect 
MAP-2 IR neurites at any of the concentrations tested (Fig. 5; 1.5 (aM, t=0.29, 
p=0.774: 3.0 |aM, t=-0.25, p=0.803; 6.0 |aM, t=-0.37, p=0.714: 12.0 |aM, t=-0.76, 
p=0.456: df=22 for all conditions). 
The length of tau IR processes were also examined. Exposure to TF-AL 
significantly decreased the length of tau IR processes at all concentrations above 
1.5 [aM (Figs. 6A. 6B and 7; 0.75 jaM, t=1.75, p=0.094: 1.5 nM, t=1.66, p=0.112: 
3.0 [aM, t=8.02, p<0.0001; 6.0 ^M, t=8.60, p<0.0001: df=22 for all conditions). 
ATF+AL similarly did not significantly affect tau IR neurites at any of the 
concentrations tested (Fig. 7; 1.5 jaM. t=-1.09, p=0.289: 3.0 jaM, t=-1.11, p=0.278; 
6.0 [aM, t=-0.46, p=0.649: 12.0 [aM, t=-1.41, p=0.171; df=22 for all conditions). 
Detection of Aluminum in Celis 
On both Day 0 and Day 4 hippocampal cultures were exposed to either 
ATF+AL or TF-AL. At 3 or 24 h, the cultures were histochemically processed for 
intracellular aluminum using morin. Neurons exposed to TF-AL on day 0 had no 
detectable staining at 3 h. At 24 h, however, the few surviving neurons were 
positive for intracellular aluminum (Figs. 8A and B). In contrast, neurons exposed 
to TF-AL on day 4 had intracellular aluminum, as indicated by flourescence, as 
early as 3 h post exposure. These cell continued to be positive at 24 h (Figs. 8C 
and D) Positive staining was only observed when cells were exposed to TF-AL. 
Control cultures and cultures exposed to ATF+AL had no detectable staining. 
Fig. 1. Hippocampal neurons were exposed to TF and AL at both Day 0 and 
Day 4. At 24 h post-exposure, the neuronal survival of Day 0 neurons was 
significantly reduced when neurons were exposed to (A) 6 p,l\/l AL-TF compared 
to (B) 6 jaM TF alone. In contrast, when Day 4 neurons were exposed to (C) 6 
fxM AL-TF for 72 h, the survival was not significantly different from (D) 6 [xM TF 
alone. 

Fig. 2. Hippocampal neurons were exposed to TF and AL on Day 0. At 24 h 
post-exposure, the survival of Day 0 neurons exposed to TF-AL was significantly 
reduced at concentrations 3.0 jiM and above compared to TF alone. The survival 
of neurons exposed to ATF+AL, however, was not significantly different from TF 
alone. Values are means and SEM; n=12 in 3 separate replications; initial cell 
number was determined at 1 h post-plating by counting from 4 randomly selected 
sites per well. 
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Fig. 3. Hippocampal neurons were exposed to TF and AL on Day 4. At 72 h 
post-exposure, the survival of Day 4 neurons was quantified. No significant 
differences in survival were observed at any of the concentrations tested for either 
TF-AL or ATF+AL compared to TF alone. Values are means and SEM; n=12 in 3 
separate replications; initial cell number was determined at 1 h post-plating by 
counting from 4 randomly selected sites per well. 
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Fig. 4. Hippocampal neurons were exposed to TF and AL on Day 4. At 72 h 
post-exposure, the cultures were processed for MAP-2 and tau 
immunohistochemistry. Process lengths were measured by image analysis. 
When neurons were exposed to (B) 6 [xM AL-TF, the lengths MAP-2 IR neurites 
were significantly reduced compared to neurons exposed to (A) 6 |aM ATF. 
Measurement of tau IR neurites also revealed reductions process length when 
neurons were exposed to (D) 6 nM AL-TF as compared to (C) 6 [xM TF. 

Fig. 5. Hippocampal neurons were exposed to TF and AL on Day 4. At 72 h 
post-exposure, the cultures were processed for MAP-2 immunohistochemistry. 
Process lengths were measured by image analysis. When neurons were exposed 
to TF-AL, the lengths of MAP-2 IR neurites were significantly reduced at 
concentrations 1.5 piM and above. ATF+AL, however, did not significantly affect 
MAP-2 IR neurite length at any of the concentrations tested. Values are the 
means and SEM; n=12 in 3 separate replications; Images were captured from 4 
preselected sites in each well. 
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Fig. 6. Hippocampal neurons were exposed to TP and AL on Day 4. At 72 h 
post-exposure, the cultures were processed for tau immunohistochemistry. 
Process lengths were measured by image analysis. When neurons were exposed 
to TP-AL, the lengths of tau IR neurites were significantly reduced at all 
concentrations 1.5 fxM and above. ATP+AL, however, did not significantly affect 
tau neurite length at any of the concentrations tested. Values are the means and 
SEM; n=12 in 3 separate replications; Images were captured from 4 preselected 
sites in each well. 
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Fig. 7. Hippocampal neurons were exposed to TF and AL on botli Day 0 and Day 
4. Using the histochemicai stain, morin, intracellular aluminum was detected. At 
24 h post-exposure, there were few surviving Day 0 neurons (A). Many of these 
neurons did, however, exhibit a characteristic somal staining pattern for 
intracellular aluminum (B). Similarly, most Day 4 neurons (C) were positive for 
intracellular aluminum (B). 
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DISCUSSION 
Because the aluminum ion does not appear to be capable of crossing the 
blood brain barrier, it seems likely that a carrier protein such as transferrin may be 
involved52. In support, transferrin has been found to be the sole plasma binding 
protein for aluminum in chronic renal dialysis patientsn. Although the distribution 
of transferrin receptors in the brain is said to have a peptide-like distribution, this 
distribution does not correlate well with areas high in ironis.aa. Frequently, 
however, there are fibers that project from neurons with high densities of 
transferrin receptors to regions that are iron rich22. It has been postulated that 
iron may be transported down the axon to secondary neuronsi4,22. The situation 
for aluminum, on the other hand, seems quite different. In patients suffering from 
DES, aluminum is deposited in regions that are dense in transferrin receptoras. 
These studies suggest that iron and aluminum may have similar mechanisms of 
transport to neurons via the transferrin receptor. Once iron enters the neuron, it 
may be transported down the axon to a secondary site. Aluminum, however, 
appears to accumulates once it enters the neuron. 
In the present study, we exposed cultured hippocampal neurons to 
aluminum chelated to transferrin (TF-AL). Using morin we analyzed the 
accumulation and uptake of aluminum by these cells. At 4 days post-plating, 
neurons exposed to TF-AL had intracellular aluminum that was detectable by 
morin stain as early as 3 h post-exposure. Similar to previous reports6i,62, the 
aluminum stain was most intense in the nucleus and soma. In contrast, even after 
24 h, aluminum was not detectable in neurons exposed to apotransferrin alone or 
ATF+AL. Thus our results indicate that the neuronal uptake of aluminum is 
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enhanced when aluminum is complexed to transferrin. Shi and Haugza using 
neuroblastoma cells reported comparable results. At physiological pH, free 
aluminum was not taken up by neuroblastoma cells. Uptake was, however, 
significantly enhanced by the use of transferrin. 
In contrast, after a 3 h exposure, neurons exposed on day 0 did not have 
detectable intracellular aluminum in any of the conditions tested. Swaiman and 
colleaguesse reported that the binding of transferrin to cortical neurons is 
dependent on the maturity of the cultures. Because our neurons were relatively 
immature, the number of functional transferrin receptors was likely to have been 
limited. If this were the case, transferrin mediated aluminum uptake may also 
have been limited. We cannot, however, rule out the possibiliy that undetectable 
levels of aluminum gained entry and/or that younger neurons are more 
susceptable to aluminum's effects. Extreme toxicity was observed in parallel 
cultures exposed to TF-AL for 24 h and many of the surviving neurons were 
positive for intracellular aluminum. The role TF-AL in this neurotoxicity will require 
further investigation. 
It is possible that the toxicity which occurred in our cultures was due to 
aluminum uptake that was not mediated by the transferrin receptor. It has been 
reported that fatty acids can promote the uptake of aluminum by neurons, 
possible by forming aluminum-fatty acid complexesss. However, because no 
toxicity was observed in our cultures when neurons were exposed to non-
complexed aluminum ATF+AL, transferrin was necessary. Free aluminum may 
exist as several different hydroxyl species in aqueous solution (personal 
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communication with G.V. Johnson). Therefore, it is possibly that transferrin 
prevented the speciation of aluminum, making it more accessible to complex with 
fatty acids. 
Alternatively, toxicity may have occurred as a result of oxidative stress and 
free radical generation facilitated by aluminum. Aluminum ions have been shown 
to stimulate iron (Fe II) dependent lipid peroxidations,21,51. in addition, aluminum 
inhibits superoxide dismutasesa. The resulting higher levels of superoxide anions 
may then complex with aluminum forming a much stronger oxidantze. Moreover, it 
is possible that when transferrin is already chelated to a metal (aluminum in this 
case), it becomes less potent in its ability to protect against iron catalyzed 
peroxidation. This theory may explain why we observed toxicity in Day 0 cultures, 
but saw no significant neuronal cell death in Day 4 cultures. Transferrin-metal 
complexes are known to be taken into cells via the transferrin receptors?,56. Due 
to pH changes, the metal is released and the apo-form of transferrin is 
recycled:,56. In our Day 4 cultures, although aluminum accumulated intracellularly, 
iron-related oxidative stress may have been reduced by recycled apotransferrln. 
Immunohistochemstry for the microtubule associated proteins, MAP-2 and 
tau was performed on neurons exposed on day 4. Changes in the lengths of 
MAP-2 and tau immunoreactive (IR) processes were analyzed after 72 h. TF-AL 
significantly reduced the lengths of both MAP-2 and tau IR processes. Johnson 
and colleagues26 similarly reported changes in MAP-2 when rats were exposed to 
dietary aluminum for periods of up to 14 months. In their study, using both 
western blots and immunohistochemistry, hippocampal MAP-2 IR was significantly 
decreased when rats were exposed to aluminum. Johnson's study, however, did 
not find a significant reduction in tau IR. This discrepancy between the present 
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study and Johnson's study may be related to reports that tau behaves differently 
in dispersed cultured hippocampal neurons as opposed to hippocampal neurons 
in situ. Dotti and colleaguesia reported that in situ tau becomes axonally 
compartmentalized, whereas in dispersed cultures an immature isoform of tau 
persists and tau remains distributed throughout the cell. 
In our study, the decreased length of l\/IAP-2 and tau IR processes may 
have been due to many factors. Among them is the possibility that aluminum 
binds directly to tau and MAP-2 altering the structure of each peptide and the 
availability of antibody epitopes. This being the situation, recognition of l\/IAP-2 
and tau by our monoclonal antibodies may have been affected, decreasing 
immunoreactivity. Alternatively, aluminum may have caused increased protein 
degradation and/or decreased protein expression. Several studies have indicated 
that aluminum affects cells by interacting with nucleotides27.63 and phosphorylated 
proteinsi2,24,68. For example, when rabbits were treated with aluminum, brain 
mRNA levels for alpha-tubulin4o and the 68 kDa neurofilament subunit4o,42 were 
significantly reduced. Interestingly, a similar finding has been reported for mRNA 
levels of tubulins and the 68 kDa neurofilament subunit from the Alzheimer's 
cortex9.36 Because aluminum is known to bind directly to DNAea and increase 
cyclic adenosine monoposphate (cAMP) levelszs, transcription may be blocked as 
a result of altered promoter phosphorylation or direct interference with the DNA 
coding for cytoskeletal proteins. In addition, Lukiw and colleaguesai have shown 
that aluminum enhances the stability of linker histone-DNA complexes, potentially 
blocking DNA transcription. 
Altered protein distribution or degradation may have produced the 
observed changes in the lengths of MAP-2 and tau IR processes. For example. 
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because the transport of some cytoskeletal proteins to their appropriate neuronal 
compartments (i.e., soma, dendrite or axon) appears to be dependent upon 
phosphorylation states4i, abnormal phosphorylation might result in a build up of 
cytoskeletal proteins within the soma at the expense of the neurites. Aluminum 
has been shown to escalate levels of cAMPzs. Increased cAMP could result, 
directly or indirectly in altered phosphorylation and/or changes in the normal 
degradation of the cytoskeletal proteins, MAP-2 and tau. In addition, aluminum 
has the potential to cause aggregation leading to abnormal accumulation of 
cytoskeletal proteins and disrupted transport. In vitro, aluminum induces the 
aggregation of highly phosphorylated cytoskeletal proteinsis. Further, when 
cultured rat neuronsso or NB2a/dl neuroblastoma cells54 were exposed to 
aluminum they developed abnormal neurofilamentous inclusions. Similarly, an 
abnormal accumulation of neurofilamentseo,66,67 and a dying back of dendritic 
trees48 have been observed when rabbits were given aluminum centrally. 
In summary, our study supports the theory that aluminum uptake by 
neurons is mediated via transferrin and the transferrin receptor. Further, we 
demonstrated that the presence of aluminum can lead to pathological changes in 
cultured neurons. In view of the number of neurodegerative diseases that have 
ties to aluminum, it is important that we fully understand aluminum's transport in 
the body and uptake by the brain and neurons. Although it is unknown whether 
aluminum plays a causal role or whether aluminum accumulation occurs after the 
disease is already in progress, we should not disregard its presence. Continued 
research will be necessary to fully understand aluminum's role and why aluminum 
accumulates in these diseases. 
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SUMMARY 
p-amyloid (pA4) is a peptide that abnormally deposits in diseases such as 
Alzheimer's disease (AD). Recent evidence has suggested that the active portion 
of pA4 corresponds to amino acids 25 to 35 (p25-35). This peptide has both 
neurotrophic and neurotoxic effects on cultured neurons. Since amyloid in the 
mature AD plaque is aggregated and relatively immobile, the present study 
attempted to simulate effects of an established AD plaque by exposing 
hippocampal neurons to aged p25-35 coated onto the culture surface. We report 
that neurons have an affinity for p25-35, and that |325-35 supports the attachment, 
growth and survival of cultured hippocampal neurons. The survival of neurons 
exposed to p25-35, however, was serum dependent. When hippocampal neurons 
were serum deprived, significant p25-35 neurotoxicity was observed compared to 
serum-deprived control cultures. These results may explain some of the 
inconsistencies that have been reported for the effects of amyloid in culture. 
Further, they support the theory that déficiences in AD contribute to 
neurodegeneration. 
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INTRODUCTION 
Neuritic plaques seen in Alzheimer's disease (AD) are characterized by 
focal neurite degeneration and the accumulation of a 4.2 kDa polypeptide known 
as p-amyloid (pA4)6.io,i8. Recent evidence indicates that pA4 is cleaved from a 
much larger, naturally occurring p-amyloid precursor proteinis. The mechanisms 
of pA4 accumulation and ultimately plaque formation, however, are yet to be 
determined. 
Recently, a number of studies have evaluated the neurotoxic effects of pA4 
using neuronal tissue culture techniques. Unfortunately, these studies have been 
controversial because pA4 and its fragments elicit both neurotrophic and 
neurotoxic effects. For example, a synthetic peptide corresponding to the first 28 
amino acids of |3A4 (pi-28) increased the survival of cultured hippocampal 
neurons2i. Subsequently, it was shown that pi-40 not only enhanced survival, but 
also promoted neurite elongation and branchingso. Pike and colleagesis 
concurred that solubilized pA4 promoted neuronal outgrowth, but also reported 
that aged pA4 was neurotoxic to hippocampal neuronsi4-i6. These studies 
suggested that pA4 neurotoxicity is related to peptide aggregation. The level of 
neuronal maturity also appears to plays a role in pA4's effects. Yankner and 
coIleages24 demonstrated that pA4 is toxic to mature hippocampal neurons and 
trophic to immature neurons. That study, as well as a study by Mattson and 
colleagesn, indicated that the toxic portion of pA4 corresponds to peptides 25 to 
35 (P25-35). 
Although the amyloid found in the AD neuritic plaque is relatively immobile 
and insoluble, most previous tissue culture studies have sought to determine 
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amyloid's effects by solubilizing it or suspending it in culture medium. In the 
present study, an alternative method was utilized where synthetic P25-35 was 
Immobilized onto the culture surface and hippocampal neurons were seeded 
directly on top of it. Using this system, we report that neurons have an affinity for 
P25-35 and that p25-35 supports the attachment, growth and survival of 
hippocampal neurons. We further report that amyloid induced neurotoxicity when 
neurons were serum deprived. 
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MATERIALS AND METHODS 
Synthesis of ^25-35 and Scrambled Peptide 
P25-35 and a scrambled peptide of the following sequences were 
synthesized by the Iowa State University Protein Facility: H-Gly-Ser-Asn-Lys-Gly-
Ala-Ile-lle-Gly-Leu-Met-OH and H-lle-Met-Leu-GIy-Asn-Gly-Ala-Ser-lle-Gly-OH, 
respectivelyn. The synthesis was performed at the 0.5 mmol level using PAM 
resins linked to the appropriate amino acids and BOC-amino derivatives. The 
resin and protected amino acids were purchased from Applied Biosystems, Inc. 
The amino acids that required side chain protection were as follows: Lys (Cl-Z) 
and Ser (Bzl). The synthesis was performed on the Applied Biosystems Model 
430A Synthesizer using standard protocols with N-methylpyrrolidone substituted 
for dimethyl formamide as the solvent. All supplies were purchased from Applied 
Biosystems, Inc. with the exception of dimethylchloride which was purchased from 
Burdick and Jackson. A quantitative ninhydrin reaction was performed on a small 
portion of the peptide after each coupling, the percentage coupling for each 
residue were all greater than 99%. 
The amino acid analysis of the major peak from a high performance liquid 
chromatograph run of the crude material was performed. An Applied Biosystems 
Model 420A Derivatizer equipped with an Applied Biosystems Model 130A 
separation system and a 920A data system was used for the analysis. The 
stoichiometric ratios of amino acids for both peptides matched their sequence. 
Both peptides were purified at the Microchemical Facility, (Institute of 
Human Genetics, University of Minnesota) using a Spectra Physics preparative 
HPLC and a Vydac C-18 column with detection at 220 nm. The scrambled 
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peptide was loaded in water while p25-35 was loaded in 40% acetonitrile/DMF 
(1:1) in water. The following gradient was used; T=0, B%=0; T=2, B=0; T=32, 
B%=60 with a flow rate of 8ml/min. Buffer A was 0.1% TFA in water and buffer B 
was 0.1% TFA in acetonitrile. The corresponding major peaks of each peptide 
were lyophilized and analyzed using a Hewlett Packard 1090 microbore analytical 
HPLC. 
Substrates 
Stock solutions of synthetic peptides were dissolved in Millipore-filtered 
double-distilled water (ddHaO, pH 7.2, 10 mg/ml) and allowed to age for at least 2 
days. At that time, aggregates of P25-35 were clearly visible. The working 
concentrations of each peptide (100 mg/ml) were prepared by further dilution in 
ddHaO. Culture plates (24-well, Corning) were treated by allowing 100 ml of either 
P25-35 or scrambled peptide to air dry directly onto the plastic surface. The wells 
were then washed with MEM prior to inoculation, in order to more dramatically 
demonstrate the adherance of neurons to p25-35, patterned p25-35 substrates 
were also prepared in 35 mmz culture dishes (Corning) using plastic 
micropipettes. Additionally, where noted, polyethylimine (PEI, 0.5 mg/ml, Sigma 
#P-3143) diluted in 150 mM sodium borate buffer was used to coat the culture 
surfacei7. In all experiments, the solvent (Millipore-filtered double distilled water, 
pH 7.2) was substituted for peptide as an additional control. The presence of p25-
35 was verified by Congo redi. 
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Hippocampal Cultures 
Hippocampi dissected from E17 rats (Holtzman) were dissociated and 
frozen in MEIVI supplemented with 10% fetal bovine serum (FBS, Gibco, lot 
#37N2517), glutamine, potassium chloride, sodium pyruvate, gentamicin, and 8% 
DMSO as previously describedi2.i3. At plating time, frozen neurons were thawed 
and pelletted by centrifugation (10 min at 100 g). The cells were then 
resuspended in fresh MEM and seeded into 24-well culture plates previously 
prepared with peptide. After 1 h (37°C, 95% room air/5% CO2 environment), the 
cultures were washed and medium was replaced with fresh medium with or 
without 10% FBS. In some experiments, peptide (0, 25, 50 or 100 mg/ml) was 
included in the plating medium and culture well surfaces were prepared using 
polyethylimine. 
Cell counts were taken by capturing 3 random images per well using a 
Nikon Diaphot phase contrast microscope equipped with a stage incubator (37°C, 
95% room air/5% CO2 environment), a GP-MF 200-2 Panasonic CCD camera and 
a VP-1500 Seikosha video copier. At 1 h all attached cells were counted, 
however, at later times only vacuole-free cells with smooth and round somas and 
nonfragmented processes were counted as viable neuronsn.is. All experiments 
were performed in triplicate with 4 wells per condition per replication. 
Scanning Electron Microscopy 
Specimens were prepared by adding p25-35 (100 mg/ml) to a hippocampal 
cell suspension and plating as described above. After 1 h, the plating medium 
was collected in 1.5 ml centrifuge tubes and spun for 10 min at 100 g. The pellet 
was then fixed with 3% gluteraldehyde (1 h; pH 7.2, 27°C) followed by incubation 
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in 1% Osmium tretroxide (1 h; 27°C). After deliydration In ethanol and 
hexmethyldisilazane (HMDS), the sample was air dried onto 12 mma glass 
coverslips or a cellulose membrane (Millipore) and sputter coated in a Polaron 
E5100 unit with a gold target. A JOEL JSM-35 scanning electron microscope 
(SEM) at 25 kV was used for examination and images were recorded on Polaroid 
665 P/N film. 
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RESULTS 
Neurons Grown on Peptide-Treated Substrates in the Presence of Serum 
Hippocampal cells plated in the presence of serum were allowed to 
attached to either p25-35, scrambled peptide or ddHaO treated substrates for 1 h. 
Neurons plated on P25-35 treated substrates appeared flattened over a relatively 
large surface area and were much less spherical in appearance (Fig. 1B) 
compared to neurons grown on scrambled peptide or ddHzO treated surfaces 
(Fig. 1A). After 2 days in vitro cells grown on scrambled peptide (Fig. 1C) or 
ddHaO treated substrates were highly clustered or detached. In contrast, the 
majority of cells grown on p25-35 treated substrates were adherent pyramidal 
shaped neurons (Fig. 1D). Further, the survival of neurons grown on p25-35 
treated substrates was significantly enhanced compared to the survival of neurons 
grown on ddHsO treated substrates (Fig. 2; t=27.22, df=22, p<0.0001). The 
survival of neurons grown on scrambled peptide, however, did not differ from 
control (Fig. .2; t=1.06, df=22, p=0.3). Preferential attachment and survival was 
also observed when cells were grown on a patterned p25-35 substrate (Fig. 3). In 
addition, at 7 days, cells grown on p25-35 treated substrates (Fig. 4A) had better 
survival rates than cells grown on PEI treated substrates (Fig. 4B; t=2.24, df=22, 
p=0.036). 
Neurons Grown on Peptide-Treated Substrates Without Serum 
Neurons plated under serum-deprived conditions were also allowed to 
attached to each of the treated substrates for 1 h. Regardless of the condition, 
the majority of neurons were morphologically similar in appearance and highly 
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adhesive (Figs. 5A and 5B). After 2 days in vitro, neurons grown on scrambled 
peptide continued to have survival rates that were similar to the ddHzO treated 
substrate (Fig. SC; t=1.80, df=22, p=0.086). In contrast, the survival of neurons 
exposed to p25-35 was significantly reduced compared to neurons grown on 
ddHaO treated substrate (Figs. 5D and 6; t=28.24, df=22, p<0.0001). By 3 days 
in vitro, however, survival on both the scrambled peptide and ddHzO treated 
substrates had also fallen, possibly suggesting that p25-35 accelerated cell death 
under serum deprived conditions. 
Peptides Added to Plating Medium 
Hippocampal neurons were plated in culture medium containing 0, 25, 50 
or 100 mg/ml of either p25-35 or scrambled peptide. After 1 h, the number of 
cells attached to the bottom of the each (PEI-coated) well was determined. p25-
35 in solution significantly reduced the number of cells attached to each well at all 
concentrations tested compared to comparable concentrations of scrambled 
peptide (Fig. 7; p<0.0001 at all concentrations). It was further observed that p25-
35 quickly formed floating aggregates when added to culture medium. SEM 
revealed that these p25-35 aggregates were heavily decorated with cells that did 
not appear to have been merely trapped in the aggregate (Fig. 8). These findings 
further suggest that hippocampal neurons have an affinity for p25-35. 
Fig. 1. Hippocampal neurons plated in serum containing medium. One hour after plating, cells attached to both 
the (A) scrambled peptide and the (B) p25-35 substrates. By 2 days, however, neurons were clustered and 
detached from the (C) scrambled peptide substrate. In sharp contrast, neurons continued to adhere and survive 
on (D) P25-35. 

Fig. 2. P25-35 treated substrates enlianced neuronal survival when serum was 
present in medium. Cells were seeded onto p25-35 (diamond), scrambled 
peptide (triangle) or ddHaO treated surfaces (circle) and maintained for 3 days. 
During the entire period, the survival of neurons grown on p25-35 treated 
substrates was significantly higher than that of neurons grown on the ddHaO 
treated surfaces. Cells grown on the scrambled peptide had survival similar to 
cells grown on ddHsO treated surfaces. Values are means and SEM; n = 12 in 3 
separate replications; initial cell number was determined at 1 h post plating. 
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Fig. 3. Hippocampal neurons preferentially attached and survived on a patterned 
substrate of p25-35 when serum was present in medium. p25-35 was applied to 
the culture surface using a plastic micropipette. After air drying and washing, 
neurons were seeded into the culture dish using serum containing medium. By 3 
days post plating, surviving neurons could only be found on the p25-35 pattern. 
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Fig. 4 After 7 days, hippocampal neurons continued to survive on p25-35 treated substrates if serum was 
present in medium. Neurons were plated in wells prepared with either p25-35 or PEI. They were then 
maintained in serum containing medium for 7 days. The survival hippocampal neurons grown on (A) p25-35 
treated substrates was significantly enhanced compared to the survival of neurons grown on a (B) PEI treated 
substrate. 
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Fig. 5. Hippocampal neurons plated in medium without serum. One hour after plating, cells attached to both the 
(A) scrambled peptide and the (B) P25-35 substrates. After 2 days, neurons continued to adhere and survive on 
the (0) scrambled peptide substrate, but had largely degenerated on (D) p25-35 (arrow on cell body). 

Fig. 6. P25-35 treated substrates prematurely decreased neuronal survival when 
serum was not present in medium. Cells were seeded onto p25-35 (diamond), 
scrambled peptide (triangle) or ddHaO treated surfaces (circle) and maintained 
for 3 days. During the first 2 days, the survival of neurons grown on p25-35 
treated substrates was significantly reduced compared to that of neurons grown 
on the ddH20 treated surfaces. Cells grown on the scrambled peptide had 
survival similar to cells grown on ddHzO treated surfaces. . However, by day 3, 
survival was comparable in all conditions. Values represent means and SEM; 
n=12 in 3 separate replications; initial cell number was determined at 1 h post 
plating. 
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Fig. 7. P25-35 solubiiized in the plating medium decreased the number of 
neurons attached to the dish. Cells were seeded with various concentrations of 
either p25-35 (diamond) or scrambled peptide (triangle) in the plating medium. 
After 1 h post-plating, the number of cells attached to the surface of the dish were 
quantified. At all concentrations tested, p25-35 significantly reduced the number 
of cells attached to the dish compared to equivalent concentrations of scrambled 
peptide. Control cultures were prepared with solvent (ddHzO) but no peptide. 
Values represent means and SEM; n=12 in 3 separate replications. 
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Fig. 8. Neurons attached to floating p25-35 aggreagates. Cells were seeded with 
P25-35 (100 mg/tni) in the plating medium. After 1 h post-plating, the medium 
was collected and the p25-35 aggregates were removed by centrifugation. SEM 
revealed that the aggregated were heavily decorated with cells. 
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DISCUSSION 
p-amyloid (pA4), the primary protein component of the neuritic plaque, has 
been a focus of attention for Alzheimer's research. It is a 4.2 kDa 
polypeptides,10,18 that is derived from a much larger molecule, p-amyloid precursor 
protein (pAPP)i9. In tissue culture, it has been demonstrated that aggregated 
synthetic analogs of pA4 are neurotoxic to cultured neuronsi4-i6. However, these 
studies and others have attempted to determine effects of pA4 by solubilization or 
suspension in culture mediumi 1,20-24. Since amyloid in the neuritic plaque appears 
to be relatively immobile and insoluble we have employed an alternative method 
for the evaluation of neuronal responses to pA4; i.e. neurons were exposed to an 
aggregated amyloid peptide coated onto the culture surface. 
It has previously been suggested that neurons have an affinity for 
aggregated amyloid fragments^ possibly via a specific interaction with a neuronal 
cell surface moIecule9,25. As such, neurotoxicity to free-floating aggregated 
amyloid could result from mechanical damage and membrane perturbation 
caused by the movement of amyloid aggregates anchored to specific cell surface 
molecules on neuronal membranes. Pike and colleagues# used a synthetic 
homologue to the 20-29 region of pancreatic islet amyloid polypeptide to control 
for non-specific neuronal interactions with aggregated peptides. However, since 
this peptide had an appearant lack of affinity for cellular surfaces#, it did not 
control for mechanical damage caused by an aggregate that adheres to a 
neuronal surface. By immobilizing amyloid to the culture surface, our study 
addressed this concern, minimizing the likelihood of mechanical damage. 
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The neuronal affinity for p25-35 was clearly demonstrated by plating 
neurons on a patterned substrate of p25-35. Neurons selectively attached and 
survived on the amyloid pattern. Similarly, when p25-35 was included in the 
plating medium, the number of neurons attached to the surface of the dish was 
significantly reduced in a dose dependent fashion. SEM revealed that aggregates 
of P25-35 collected from the plating medium were heavily decorated with cells. 
These findings strongly suggest that neurons have an affinity for aggregated p25-
35. This affinity may be due to a specific receptor or cell surface molecule that 
binds amyloid. For example, when NB41A3 neuroblastoma cells were exposed to 
pi-40, specific surface binding of pi-40 occurredas. While the aggregation state 
of this peptide was not reported, it may have been important to the recognition pi -
40, since binding did not occur until after a 20 h incubation. In another study, 
Kozlowski and coHeagess have reported that the carboxy-terminal 104 amino acid 
of pAPP bind with high affinity and specificity to a cell surface molecule on PC12 
cells. Since this fragment contains the pA4 domain and has the tendency to self-
aggregate4, it is likely, that aggregated P25-35 may also interact with a specific 
cell surface molecule on hippocampal pyramidal cells. 
We further observed that p25-35 treated substrates supported the 
attachment and long term survival of hippocampal neurons when maintained in 
the presence of serum. By 2 days neurons on the p25-35 substrate had 
significantly better survival rates than neurons plated on scrambled peptide or 
untreated substrates. Whitson and colleagesai demonstrated that a peptide 
homologous to the first 28 amino acids of pA4 (p1-28) enhanced the survival of 
hippocampal pyramidal neurons. Subsequently, it was shown that pi-42 
increased not only survival, but also promoted neurite elongation and branchingzo. 
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Assuming tliat some level of peptide aggregation and precipitation onto the 
culture surface occurred in these studies, our findings are comparable. In the AD 
brain, such neuronal responses may account for the aberrant neuronal sprouting 
that occurs in plaque containing regionss. 
Yankner and colleagues24 reported that amyloid fragments were 
neurotrophic to cultured immature neurons (up to 2 days) and neurotoxic to 
mature neurons (3 or more days). In his study, cultures were maintained in a 
serum containing medium. We likewise observed that amyloid could promote the 
survival and support the growth of neurons maintained in serum containing 
medium. However, even after 7 days in vitro, there was no amyloid-induced 
neuronal death (serum present). Amyloid-induced neuronal death only occurred 
when cells were serum deprived. Further, this cell death occurred in neurons that 
were relatively immature (2 days in vitro) compared to those in Yankner's study. 
We have also observed similar results in experiments using pi-40 and p25-35 
purchased from Bachem (unpublished observations). 
One explanation for the results of our study may be that amyloid is directly 
neurotoxic and that some unidentified serum factor or factors protect against 
amyloid-induced neuronal death. For example, compounds such as substance 
Pa,24, vitamin E and other anti-oxidantsz have reportedly blocked amyloid toxicity. 
If these or other protecting factors are present in serum, amyloid-induced 
neurotoxicity may have been blocked in any of our experiments that used serum. 
If this were the case, amyloid-induced neurotoxicity would most likely vary with 
each lot of serum. Any significant variance may account for some of the 
inconsistencies that have been reported in studies of amyloid toxicity. 
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Alternatively, our results may imply that amyloid renders neurons more 
vulnerable to the effects of deficiencies or toxicants. For example, mature cortical 
neurons transiently deprived of glucose were only slightly damaged. However, 
when these cells were exposed to a synthetic amyloid peptide, the effects of 
glucose deprivation were intensifieda. Moreover, Koh and colleagues? 
demonstrated that the survival of mouse cortical neurons was not directly affected 
by exposure to amyloid. Instead, amyloid increased neuronal vulnerability to low 
levels of excitatory amino acids (EAA). Likewise, in an independent study by 
Mattson and colleaguesn, it was shown that human cortical neurons exposed to 
P25-35 or pi-38 were more susceptible to excitotoxicity. Mattson and 
colleaguesn further indicated that amyloid peptides affect excitotoxicity by 
disrupting resting neuronal calcium levels and by enhancing calcium responses to 
EAAs and calcium ionophore. These studies all suggest that amyloid acts by 
increasing neuronal vulnerability to other factors. In our study, when neurons 
were stressed by serum deprivation, cell death was accelerated when cells were 
grown on P25-35 treated substrates. Similarly in the AD brain, the effects of 
deficiencies, imbalances or toxic compounds may be potentiated by exposure to 
amyloid. 
It is important to mention that the direct or indirect pathogenic role of 
amyloid in AD is still unclear. This study and others have shown that the 
biological effects amyloid are complex in nature. Clearly future studies will be 
necessary to determine the exact role of pA4 in AD. It is hopeful that with these 
studies, a means to prevent or treat Alzheimer's disease will be developed. 
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SUMMARY 
p-amyloid (pAP) is a peptide that abnormally deposits in diseases such as 
Alzheimer's disease (AD). Recent evidence has suggested that the active portion 
of pAP corresponds to amino acids 25 to 35 (p25-35). This peptide has both 
neurotrophic and neurotoxic effects on cultured neurons. Because amyloid in the 
mature AD plaque is aggregated and relatively immobile, in a previous study we 
attempted to simulate effects of an established AD plaque by exposing 
hippocampal neurons to aggregated P25-35 coated on the culture surface. 
Neurons had an affinity for p25-35 and p25-35 supported the attachment, growth 
and survival of cultured hippocampal neurons when grown in the presence of 
serum. However, p25-35 neurotoxicity occurred when neurons were serum 
deprived. In the present study, using the same culture system, we have further 
examined p25-35 toxicity using culture medium supplemented with modified N2 
(MN2) or each of its components (ie. progesterone, insulin, rat apotransferrin, 
putrescine and sodium selenite). When medium was supplemented with MN2, 
P25-35 supported the attachment, growth and survival of cultured hippocampal 
neurons. When neurons were exposed to each component of MN2 individually, 
only rat apotransferrin and sodium selenite significantly protected against P25-35 
toxicity. In view of the antioxidant properties of these compounds, vitamin E was 
also tested. Vitamin E supplemented medium significantly protected against p25-
35 neurotoxicity. This survival was comparable to neuronal survival in medium 
containing MN2. These findings are supportive of the theory that free radical 
generation may be involved in amyloid related disease such as Alzheimer's and 
that antioxidants may be useful to prevent further neurodegeneration. 
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INTRODUCTION 
In Alzheimer's disease (AD) the formation of neuritic plaques is 
characterized by focal neurite degeneration and the accumulation of a 4,2 kDa 
polypeptide known as p-amyioid (pAP) 12,21.30. While the mechanisms of pAP 
accumulation and ultimately plaque formation are still under investigation, the 
evidence indicates that pAP is cleaved from a much larger, naturally occurring p-
amyioid precursor proteinai. 
Recent studies have suggested that pAP has diverse biological activity. 
Using neuronal tissue culture techniques to evaluate effects of pAP, it has been 
demonstrated that pAP and its fragments have both neurotrophic and neurotoxic 
characteristics. For example, a synthetic peptide corresponding to the first 28 
amino acids of pAP (pi-28) increased the survival of cultured hippocampal 
neurons34. This same group subsequently provided evidence showing that pi-40 
not only enhanced neuronal survival, but also promoted neurite elongation and 
branchingsa. . Although these studies did not report toxicity, Yankner and 
colleages36 later demonstrated that pAPs effects are dependent on the age of the 
neuron. pAP was toxic to mature hippocampal neurons and trophic to immature 
neurons. They further indicated that the active portion of pAP corresponds to 
peptides 25 to 35 (p25-35). Independent groups have since also reported p25-35 
activity as well2,22 
Although the amyloid found in the AD neuritic plaque is relatively immobile 
and insoluble, most previous tissue culture studies have sought to determine 
amyloid's effects by solubilizing it or suspending it in culture medium. For 
example. Pike and colleagues27-29 tested effects of aging and aggregating pAP 
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prior to suspension in culture medium and neuronal exposure. In these studies, 
aged pAP was found to be neurotoxic to hippocampal neurons, possibly 
suggesting that pAP neurotoxicity is related to peptide aggregation. In a previous 
study, however, we utilized an alternative method for the exposure of neurons to 
aged pAP where hippocampal neurons were seeded onto aged p25-35 
immobilized on the culture surface32. Using this system, we found that under 
normal conditions p25-35 was not neurotoxic. To the contrary, neurons had an 
affinity for P25-35 and P25-35 supported the continued attachment, growth and 
survival of hippocampal neurons. Cell death in response to p25-35 only occurred 
after neurons were serum deprived. Similarly, it has been reported that pAP and 
its fragments are not directly neurotoxic; instead they enhance susceptibility to 
additional stresses such as excitatory amino acid toxicityi6 ,22. 
In the present study, we have continued our examination of p25-35 
neurotoxicity using aged P25-35 attached to the culture surface. We report that a 
modified version of Bottenstein and Sato's N2 defined media supplements, MN2, 
prevented P25-35 neurotoxicity associated with serum deprivation. Further, 
individually, the MN2 components transferrin and sodium selenite also protected 
against P25-35 neurotoxicity although less efficiently. In view of transferrin and 
sodium selenite's antioxidant qualities and a recent study suggesting that 
oxidative stress is involved in amyloid toxicityz, the antioxidant, vitamin E, was 
tested in our system. Vitamin E was found to be extremely effective at preventing 
P25-35 neurotoxicity associated with serum deprivation. In addition, staining with 
2,7 dichloroflourscin indicated that peroxide formation accompanies amyloid 
exposure in serum deprived cultures. This data suggests that altered oxidative 
stress plays a role in amyloid neurotoxicity. 
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MATERIALS AND METHODS 
Synthesis of ^25-35 and Scrambled Peptide 
P25-35 and a scrambled peptide of the following sequences were 
synthesized by the Iowa State University Protein Facility: H-Gly-Ser-Asn-Lys-Gly-
Ala-lle-lle-Gly-Leu-Met-OH and H-lle-Met-Leu-Gly-Asn-GIy-Ala-Ser-lle-Gly-OH, 
respectively22. The synthesis was performed at the 0.5 mmol level using PAM 
resins linked to the appropriate amino acids and BOC-amino derivatives. The 
resin and protected amino acids were purchased from Applied Biosystems, Inc. 
The amino acids that required side chain protection were as follows: Lys (Cl-Z) 
and Ser (Bzl). The synthesis was performed on the Applied Biosystems Model 
430A Synthesizer using standard protocols with N-methylpyrrolidone substituted 
for dimethyl formamide as the solvent. All supplies were purchased from Applied 
Biosystems, Inc. with the exception of dimethylchloride which was purchased from 
Burdick and Jackson. A quantitative ninhydrin reaction was performed on a small 
portion of the peptide after each coupling , the percentage coupling for each 
residue were all greater than 99%. 
The amino acid analysis of the major peak from a high performance liquid 
chromatograph run of the crude material was performed. The Applied Biosystems 
Model 420A Derivatizer equipped with an Applied Biosystems Model 130A 
separation system and a 920A data system was used for the analysis. The 
stoichiometric ratios of amino acids for both peptides matched their sequence. 
Both peptides were purified at the Microchemical Facility, (Institute of 
Human Genetics, University of Minnesota) using a Spectra Physics preparative 
HPLC and a Vydac C-18 column with detection at 220 nm. The scrambled 
86 
peptide was loaded in water while p25-35 was loaded in 40% acetonitrile/DMF 
(1:1) in water. The following gradient was used: T=0, B%=0; T=2, 8=0; T=32, 
B%=60 with a flow rate of 8 ml/min. Buffer A was 0.1 % TFA in water and buffer B 
was 0.1% TFA in acetonitrile. The corresponding major peaks of each peptide 
were lyophilized and analyzed using a Hewlett Packard 1090 microbore analytical 
HPLC. 
Substrates 
Stock solutions of synthetic peptides were dissolved in Millipore-filtered 
double-distilled water (ddHaO, pH 7.2, 10 mg/ml) and allowed to age for at least 2 
days. At that time, aggregates of p25-35 were clearly visible. The working 
concentrations of each peptide (100 ng/ml) were prepared by further dilution in 
ddHaO. Culture plates (24-well, Corning) were treated by allowing 50 [xl of p25-35 
to air dry directly onto the plastic surface. The wells were then stored at -20°C 
until use. Immediatedly before plating cells, the surfaces were washed with MEM. 
The presence of P25-35 was verified by Congo redi. 
Hippocampal Cultures 
Hippocampi dissected from El 7 rats (Holtzman) were dissociated and 
frozen in MEM supplemented with 10% fetal bovine serum (FBS, Gibco, lot 
#37N2517), glutamine, potassium chloride, sodium pyruvate, gentamicin, and 8% 
DMSO as previously describedi8,23,24. At plating time, frozen neurons were 
thawed and pelletted by centrifugation (10 min at 100 g). The cells were then 
resuspended in fresh MEM and seeded into 24-well culture plates previously 
prepared with peptide and the appropriate medium . 
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To test for effects by MN2, hippocampal neurons were plated on P25-35 
treated substrates in medium containing eitlier MN2, or the MN2 components, rat 
apotransferrin (10 [xg/ml), sodium selenite (30 nM), putrescine (100 nM), insulin 
(5 [xg/ml) or progesterone (20 nM). MN2 is a modified version of Bottenstein and 
Sato's N2 defined media supplements with rat transferrin substitued for human 
transferrin. In a previous study, MN2 was found to support the survival of cultured 
rat hippocampal neuronia. The dose response for transferrin and sodium selenite 
were determined using multiples of the transferrin and sodium selenite 
concentrations used in our MN2 recipe. In addition, transferrin and sodium 
selenite were tested together. Medium without supplement was used as a control 
in all experiments. To test for effects by vitamin E, neurons were again plated on 
P25-35, but the medium was supplemented with vitamin E alone. Medium without 
supplement but with the solvent (1%; 1:10 ethanol/DMSO) was used as a control 
in these experiments. 
Cell counts were taken by capturing 3 random images per well using a 
Nikon Diaphot phase contrast microscope equipped with a stage incubator (37°C, 
95% room air/5% CO2 environment), a GP-MF 200-2 Panasonic CCD camera and 
a VP-1500 Seikosha video copier. At 1 h all attached cells were counted, 
however, at later times only vacuole-free cells with smooth and round somas and 
nonfragmented processes were counted as viable neuronssz.se. All experiments 
were performed in triplicate with 4 wells per condition per replication. 
Detection of Intracellular Peroxide Formation 
Intracellular peroxide formation was detected using 2,7-dichloroflourescin 
diacetate as previously describedzs.ss. This compound is de-esterified by 
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endogenous esterases to a polar compound that Is trapped inside the cell. If 
peroxides are present within the cell, the compound is oxidized to flourescent 2, 7-
dichloroflouresceins. Hippocampal neurons were plated as described above on 
P25-35 in medium containing either MEM alone or MEM supplemented with MN2, 
sodium selenite, apotransferrin or vitamin E. After 2 d the cells were bathed in 10 
nM 2,7-dichloroflourescin diacetate for 10 min at 37°C. At that time the cultures 
were washed with HBSS and intracellular flourescence was examined using an 
epiflourescence equipped Nikon Diaphot microscope. 
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RESULTS 
Effects of MN2 and MN2 Components on ^25-35 Exposed Neurons 
After 3 days on p25-35, neuronal survival in control cultures (ie. grown in 
non-supplemented medium) was decreased to 12.5+1.19% (Figs. 1A and 2, 
n=12). Neurons grown on p25-35 in presence of MN2, however, had survival that 
was significantly enhanced compared to control (Fig. 2; t=20.86, df=22, 
p<0.0001). These MN2 neurons were largely multipolar, pyramidal shaped cells 
(Fig. IB). Viable neurons grown on p25-35 with MN2 were present even after 3 
weeks in culture (Fig. 3). Individual effects of each MN2 component were also 
considered. After 3 days in culture, only transferrin and sodium selenite protected 
neurons from P25-35 compared to control (Figs. 1C, ID and 2; t=-5.2, df=22, 
p<0.0001 for transferrin and t=-3.51, df=22, p=0.002 for sodium selenite). This 
protection however, was significantly less than protection by MN2 (t=16.19, df=22, 
p<0.0001 for transferrin and t= 18.27, df=22 , p=0.0001 for sodium selenite). 
Combined effects of transferrin and sodium selenite were also examined, but 
there was no significant increase in the survival of neurons compared to 
transferrin alone (Fig. 3; IX concentration; t= 0.13, df=22, p=0.895) or sodium 
selenite alone ( Fig. 3; IX concentration; t=1.35 , df=22, p=0.192). The dose 
response curves for transferrin and sodium selenite are also shown in Fig. 3. 
Effects of Vitamin E on Neurons Grown with ^ 25-35-Treated Substrates 
Effects of vitamin E (10, 100, 200, or 400 |xg/ml) were accessed using the 
same culture system. After 3 days in culture, survival was assessed and vitamin 
E was found to significantly enhance the survival of cells grown on p25-35 in dose 
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dependent manner up to 200 ng/ml (Figs. 4 and 5; 200 ng/ml; t=15.93, df=22 , 
p<0.0001, compared to cultures grown in non-supplemented medium). At 
concentrations above 200ng/ml, protection by vitamin E was comparable to 
protection by MN2 (Fig. 5; t=-0.74, df=22, p=0.464 for 200p,g/ml and t=0.32, 
df=22, p=0.749 for 400[ig/ml). 
Detection of Intracellular Peroxide Formation 
Cultures were exposed to p25-35 treated surfaces for 2 d in medium 
containing either MEM alone or MEM supplemented with MN2, sodium selenite, 
apotransferrin or vitamin E. At that time, the cultures were assessed for the 
formation of intracellular peroxides using 2,7-dichloroflourescin diacetate. 
Peroxides as indicated by flourescence were strongly detectable in neurons 
exposed to MEM alone (Fig. 6A). Neurons exposed to medium containing sodium 
selenite or apotransferrin had some cells with detectable flourescence (Fig. 6B, 
6C and 6D), whereas cultures grown with N-2 or vitamin E had little to no 
detectable flourescence (Fig. 6E). 
Fig. 1. Hippocampal neurons were grown on substrates treated witli p25-35. After 3 days in culture, neuronal 
survival in non-supplemented medium (A) was significantly reduced compared to survival in MN2 supplemented 
medium (B). Transferrin (C) and sodium selenite (D) were also tested individually. Both compound 
demonstrated some enhancement of neuronal survival compared neurons grown in non-supplemented medium. 

Fig. 2. Hippocampal neurons were grown on substrates treated with p25-35. 
After 3 days in culture, each individual component of MN2 was tested. Only 
transferrin and sodium selenite significantly enhanced neuronal survival compared 
to neurons grown in non-supplemented medium. The enhancement by these 
compounds was much less than enhancement by MN2, however. Values are 
means and SEM; n=12 in 3 separate replications; initial cell number was 
determined at 1 h post-plating; Abbreviations: NO SUP, no supplement; PUT, 
putrescine; PROG, progesterone; TP, transferrin; SS, sodium selenite; INS, 
insulin. 
Neuronal Survival (% of Initial Number) 
Fig. 3. Hippocampal neurons were grown on substrates treated with p25-35 in 
medium containing MN2. While the cell density was not high, neurons such as 
these were found as late as 3 weeks in culture. 

Fig. 4. Hippocampal neurons were grown on substrates treated with p25-35 for 3 
days in medium containing transferrin or sodium selenite. At concentrations 
above 1X the normal MN2 concentration, neuronal survival in medium containing 
transferrin or sodium selenite was significantly enhanced compared to neurons 
grown in non-supplemented medium (NS). The enhancement by these 
compounds, however, was significantly less than that of complete MN2. In 
addition, the combination of transferrin and sodium selenite together (single point 
at 1X concentration), did not significantly alter neuronal survival compared to 
either transferrin alone or sodium selenite alone. Values are means and SEM; 
n=12 in 3 separate replications; initial cell number was determined at 1 h post-
plating. 
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Fig. 5. Hippocampal neurons were grown on substrates treated with P25-35 for 3 
days in medium supplemented with vitamin E (200 |xg/ml). These cells were 
healthy in appearance with morphological features that are typical of hippocampal 
pyramidal neurons. 

Fig. 6. Hippocampal neurons were grown on substrates treated with p25-35 for 3 
days in medium supplemented with vitamin E. The survival of these cells at all of 
the concentrations tested was significantly better than the survival of neurons 
grown in non-supplemented medium. At concentration of 200 ng/ml and above 
the survival of cells grown in vitamin E supplemented medium was comparable to 
survival in MN2 containing medium. Values are means and SEM; n=12 in 3 
separate replications; the initial cell number was determined at 1 h post-plating. 
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Fig. 7. Hippocampal neurons were grown on substrates treated with p25-35 for 2 days. At that time, the cultures 
were stained with 2, 7-dichloroflourescin to detect the presence of intracellular peroxides. Peroxides were 
detectable in most neurons grown in non-supplemented medium (A and B). Additionally, a few cells were 
positive when neurons were grown in medium containing sodium selenite (30 nM; C and D) or Transferrin (10 
[xg/ml; E and F). Neurons grown in medium containing vitamin E (200 pig/ml; G and H), however, had little to no 
detectable fluorescence. 
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DISCUSSION 
In a previous study we exposed neurons to an aggregated amyloid peptide 
coated onto the culture surfaceis. Under normal conditions, after a 3 day 
exposure, amyloid was not neurotoxic. When neurons were serum deprived, 
however, amyloid-induced toxicity was observed. In the present study, using the 
same culture system, amyloid neurotoxicity was also induced when neurons were 
serum deprived. This toxicity was prevented by the inclusion of MN2 in the growth 
medium. 
In view of the few components involved in the MN2 supplement, we 
evaluated each separately to determine which factors contribute to MN2s 
protective qualities. Protection from amyloid neurotoxicity was only observed for 
transferrin and sodium selenite. These compounds, however, were much less 
efficient than complete MN2. Because no other MN2 component significantly 
enhanced neuronal survival, MN2 components must interact. Accordingly, we 
tested for combined effects of transferrin and sodium selenite. The protective 
effects of these compounds, however, were not additive and were well below the 
level of MN2. 
Because both transferrin and sodium selenite have antioxidant 
characteristics, oxidative stress in response to amyloid was indicated. As such, 
the antioxidant and free radical scavenger, vitamin E was tested on our culture 
system. Vitamin E protected cultured hippocampal neurons from p25-35 toxicity 
with survival rates comparable to MN2. Similarly, Behl and colleagesz using an 
amyloid-sensitive PC12 cell clone, demonstrated that vitamin E and an unrelated 
antioxidant, propyl gallate, protected against amyloid toxicity. To further support 
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the theory that oxidative stress occurred in response to amyloid we treated our 
cultures with 2,7 dichloroflourscin. This stain has been useful for the detection of 
intracellular peroxide formations,14,26. Neurons grown on p25-35 for 2 d in medium 
with no supplement were strongly labeled, while neurons grown with transferrin 
and sodium selenite had comparatively moderate labeling. In contrast, cultures 
grown with MN2 or vitamin E added to the medium had little to no staining. These 
findings strongly suggest that free radical generation and oxidative stress are 
involved in amyloid toxicity. It is unclear, however, whether amyloid is the target 
of free radicals, or whether amyloid promotes the production and/or actions of free 
radicals. 
Because transferrin protected hippocampal neurons from amyloid toxicity, it 
is possible that amyloid's effects may be associated with unsequestered iron ions. 
Dyrk's and colleaguesio reported that the aggregation of pAP or the COOH-
terminal 100 residues of the amyloid precursor protein is promoted by metal-
catalyzed oxidation of amino acids and protein cross-linking induced by free 
radical generation. Further, Pike and collegues27-29 have suggested that amyloid 
toxicity is related to peptide aggregation. In view of these reports, the amyloid 
toxicity observed in our cultures may have been promoted by iron-catalized 
aggregation of amyloid. 
Alternatively, the interaction of iron ions with oxygen may have resulted in 
the formation of highly reactive species such as the hydroxyl radical that can lead 
to lipid peroxidation and cell deathis. The antioxidant and transport protein, 
transferrin, binds free iron ions preventing reaction with oxygen. Apotransferrin 
added to our culture medium may have protected against amyloid toxicity by 
removing iron ions, thereby inhibiting iron-catalyzed lipid peroxidation. Similarly 
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selenium has been shown to have antioxidant quaiitiesa.ss. However, because 
transferrin and sodium selenite were only marginally effective compared to vitamin 
E, it is probable that other mechanisms are also involved. Interestingly, in AD, 
both vitamin E and transferrin are reportedly reduced, perhaps due to 
malnutritionis. If, as our study indicates, amyloid toxicity is related to oxidative 
stress, reduced vitamin E and transferrin levels could potentiate neuronal 
degeneration. 
Altered neuronal calcium homeostasis has also been implicated as an 
effect of pAP. Mattson and colleaguessa provided evidence that pAPs 
compromise the ability of neurons to reduce intracellular free calcium levels 
following treatment with glutamate. Amyloid exposure by itself increased 
intracellular calcium levels with longer exposure periods. These changes in 
intracellular calcium may be explained by lipid peroxidation, disruption of cellular 
membranes and/or damage to membrane bound Ca2+ATPase and the Na+/Ca2+ 
exchanger. Ca2+ATPase and the Na+/Ca2+ exchanger are primary means of 
reducing intracellular free calcium levelss. Interestingly, the neuronal Na+/Ca2+ 
exchanger is reportedly altered in AD7. 
High intracellular calcium in response to amyloid or amyloid in conjuction 
with some other factor may promote the formation of free radicals and neuronal 
degeneration. Recent work with neuronal cultures has suggested that elevation of 
intracellular calcium can activate calmodulin and nitric oxide synthetase leading to 
the release of nitric oxide (NO)4,8,i7. Surrounding cells may then be vulnerable to 
hydroxyl free radicals generated by a reaction between NO and superoxide 
anionsii or NO binding to intracellular metalloproteins4.i7. Bredt and colleages4 
reported that a select population of hippocampal neurons produce NO and those 
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cells are not affected by NO. The pattern of neuronal survival in our study is 
consistent with Bredt and colleage's study in that a selective group of 
approximately 10% of our neurons were resistant to amyloid toxicity. 
Amyloid enhanced glutamate toxicity has been reported by a number of 
independent groups2,16,22 and it appears to involve the NIVIDA glutamate receptor. 
It is possible, however, that the quisqualate receptor is also involved. Since 
glutamate and cystine compete for binding sites on the quisquallate receptor, 
glutamate toxicity may occur if cystine is displaced by glutamatese. Decreased 
cystine uptake has been shown to cause the accumulation of intracellular 
peroxides and decreased cellular levels of gIutathione25,26. Our study suggests 
that amyloid toxicity involves free radical generation and peroxide formation. If 
glutamate promotes free radical generation by decreasing glutathione, amyloid 
may enhance toxicity by producing additional free radicals or by causing cells to 
become more susceptible to oxidative stress. In either case, degeneration could 
occur if neurons are exposed to both amyloid and glutamate. This point is 
particularly salient because many of the neurons affected in AD have 
glutaminergic inputzo and glutathione levels are reportedly decreased in ADis. 
In summary, this study has provided evidence that oxidative stress is 
involved in amyloid-induced neurodegeneration. At this point, however, it is 
unclear whether amyloid induces similar stresses in vivo. Future studies 
examining amyloid and oxidative stress are clearly indicated and may lead to 
effective treatments for amyloid diseases such as Alzheimer's and Down's 
syndrome. 
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GENERAL SUMMARY 
In this dissertation I examined some effects of aluminum and amyloid, two 
compounds that are reportedly localized in the plaques and NFTs of both 
Alzheimer's and Down's syndromeia. In my first study, changes in the survival and 
neurite outgrowth of cultured hippocampal neurons were analyzed after exposure 
to aluminum and transferrin. Transferrin was used in this study because it is the 
most likely carrier protein for aluminum in wVo72. To date, there have been no 
studies that have used transferrin to mediate aluminum uptake by primary 
neuronal cultures. Freshly plated neurons that were exposed to aluminum 
chelated to transferrin (TF-AL) had greatly reduced survival rates after 24 h. 
Morin staining at 3 h revealed no aluminum uptake by these cells, although 
aluminum accumulations were found in surviving neurons after 24 h. In contrast, 
the survival of neurons that were grown for 4 days prior to being exposed to TF-
AL for 72 h was not significantly different from control. This was somewhat 
surprising because intracellular aluminum could be detected in these older 
neurons as early as 3 h post exposure. Even though survival was not altered by 
TF-AL, after a 72 h exposure, immunohistochemistry revealed a significant 
reduction in the lengths of both MAP-2 and tau immunoreactive processes. This 
study provided evidence that aluminum is neurotoxic. Further, it demonstrated a 
possible mechanism for the uptake of aluminum by neurons in neurodegenerative 
diseases such as dialysis encephalopathy syndrome and Alzheimer's disease. 
p-amyloid is the primary protein component of neuritic plaques seen in 
Alzheimer's disease and Down's syndrome45. |n Papers II and 111, I sought to 
characterize the effects of an amyloid fragment (|325-35) on cultured hippocampal 
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neurons. This fragment has been shown to be the active portion of the amyloid 
peptide^. Even though the amyloid peptide is highly insoluble in physiological 
solutions, previous culture studies have attempted to exposed cells to amyloid in 
medium. As a result, numerous inconsistencies have been reported. In Paper II, 
I sought to develop an alternative method for the exposure of cultured neurons 
where the environment would be more similar to the environment surrounding the 
amyloid found in plaques. This was accomplished by coating the culture surface 
with aged p25-35. Using this system I found that p25-35 is not inherently toxic to 
hippocampal neurons. In fact, p25-35 supported the long term survival and 
growth of cultured neurons. However, P25-35 was toxic when neurons were 
serum deprived. This study demonstrated that amyloid has diverse effects that 
depend upon the conditions of exposure. The finding that amyloid was toxic 
under conditions of serum deprivation supports the theory that deficiencies in 
amyloid related diseases contribute to neurodegeneration. 
In the final paper, 1 continued to examine effects of amyloid on cultured 
hippocampal. neurons. Using the same method of exposure that was used in 
Paper 11,1 found that serum deprived neurons were protected from amyloid toxicity 
by the inclusion of MN2 in the culture medium. MN2 is a modified version of 
Bottenstein and Sato's N2 serum replacement?. MN2 contains 5 basic 
ingredients: progesterone, insulin, sodium selenite, putrescine and apotransferrin 
substituted for human apotransferrin. To determine if one of these components 
was responsible for the protective qualities of MN2, I tested each individually. 
Only apotransferrin and sodium selenite afforded any appreciable protection. This 
protection was, however, significantly lower than that of complete MN2. 
Apotransferrin and sodium selenite were applied together, but the effects were not 
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additive. Because both of these compounds are l<nown antioxidants, I decided to 
test vitamin E in my culture system. As suspected, vitamin E was highly effective 
at preventing amyloid induced cell death. Further, vitamin E alone was 
comparable to MN2 in its ability to prevent toxicity. The effectiveness of these 
antioxidants implied that free radical generation and oxidative stress were factors 
in the amyloid induced toxicity that I had observed. As such, I stained the cultures 
with 2, 7 dichloroflourescin following exposure to amyloid. This non-flourescent 
compound is taken up by cells where it is converted to a flourescent form if 
peroxides are present. The staining of serum deprived cultures exposed to 
amyloid indicated that most of neurons were positive for peroxide formation. 
Comparatively, vitamin E and MN2 virtually eliminated all detectable peroxide 
formation, while the staining pattern for transferrin and sodium selenite fell 
somewhere in between. These results strongly suggest that amyloid toxicity 
involves oxidative stress and that antioxidants may be useful in the prevention or 
slowing of further amyloid induced neurodegeneration in patients diagnosed with 
diseases such as Alzheimer's or Down's syndrome. 
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DISCUSSION 
The focus of this dissertation was to characterize effects of two 
compounds, aluminum and amyloid, on primary cultures of hippocampal neurons. 
Boith amyloid and aluminum have been implicated in neurodegenerative diseases 
such as Alzheimer's and Down's syndromeia. Culture work with both of these 
compounds has been complicated due to their insolubility in physiological 
solutions. As such, my approach was to find alternative methods for exposing 
neurons. These methods should be more like the exposure that neurons receive 
in vivo. For example, it is very unlikely that aluminum Is transported to the brain 
as a free ion. Instead, it is reportedly complexed to transferrin^. In my culture 
system, I used transferrin to mediate the delivery of aluminum to my neurons. 
Similarly for amyloid, I sought to find a more natural and usable method for the 
exposure of neurons in culture. In both Alzheimer's and Down's syndrome, 
amyloid is concentrated at the center of focal neuritic degenerations called neuritic 
plaquesie. The amyloid in these neuritic plaques is said to be aggregated and 
highly insolubleia. Therefore, based on the morphological relationship between 
neurons and plaques and the insolubility of amyloid, it is likely that neurons are 
exposed to amyloid by direct contact with the plaques. In my cultures, I attempted 
to mimic this environment by exposing neurons to aged amyloid coated onto the 
culture surface. With this system, because my neurons were maintained in direct 
contact with the amyloid, 1 was able to effectively test amyloid toxicity. 
Shi and Hauge? demonstrated that at physiological pH aluminum is not 
taken up by cultured neuroblastoma cells. With the addition of transferrin, 
however, significant levels of intracellular aluminum were detected. In Paper I, I 
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likewise observed that the neuronal uptake of aluminum was enhanced by 
chelation to transferrin(TF-AL). Interestingly, there were age dependent 
differences in the responses of neurons to TF-AL. After a 24 h exposure, the 
survival of Day 0 neurons was significantly reduced, whereas the survival of Day 4 
neurons after a 72 h exposure was unaffected. The exact mechanism for this 
difference is unclear. While toxicity was dependent on chelation to transferrin, I 
question whether toxicity was due transferrin mediated uptake of aluminum. At 3 
h post-exposure, intracellular aluminum was detectable in 4 day neurons but not 
in freshly plated neurons. Swaiman and coileagues7o, reported that the binding of 
transferrin to cortical neurons is dependent on the maturity of the cultures. 
Because the Day 0 neurons were relatively immature, it is questionable whether 
transferrin receptors were available to receive TF-AL. Future work in this area will 
be necessary to elucidate the mechanism behind this age dependent 
susceptibility. 
In this same study I also examined the ability of TF-AL to alter neurite 
outgrowth. After a 72 h exposure to TF-AL, Day 4 neurons were processed for 
MAP-2 and tau immunocytochemistry. These proteins were chosen because their 
epitopes are found in neurofibrillary NFTss,12,22,38-41,71.81.86 and aluminum is known 
to disrupt microtubulesi3,5i. An analysis of the immunoreactive (IR) neurites 
revealed that TF-AL caused a significant reduction in the lengths of both MAP-2 
and tau IR processes. Again the mechanism behind this reduction is unknown. 
Altered phosphorylationi3,32,82, expressionso.sa and transports2 are among some of 
the possibilities that have been suggested. 
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The role of amyloid in neuronal degeneration was considered in Papers II 
and III. Recently, several groups have evaluated effects of amyloid using 
neuronal tissue culture techniques. These studies have reported that amyloid and 
its fragments elicit both neurotrophic6o,76,77,84 and neurotoxic effects4.59-6i ,83,84. | 
also observed variable results when testing amyloid in my cultures, i.e. both toxic 
and non-toxic effects. When I exposed neurons to amyloid coated onto the 
culture surface, no toxicity was observed. In fact, amyloid supported the long 
term growth and survival hippocampal neurons. When stressed by serum 
deprivation, though, neuronal survival was significantly decreased. Previous 
studies by other groups have used a variety of different culture media. Based on 
my study, it is possible that media and serum differences are responsible for 
some of the inconsistencies that have been reported with regard to amyloid's 
effects in culture. 
Amyloid was shown to have substrate characteristics that supported the 
growth and survival of hippocampal neurons grown in the presence of serum. 
These substrate qualities may be related to the membrane spanning position 
amyloid occupies as part of the amyloid precursor proteini?. Modulation of cell-
cell interactions has been postulated as a possible role for this precursor 
protein2i.36. Alternatively, amyloid may serve as a reservoir for growth and 
attachment factors. Neuritic plaques in the Alzheimer's brain have been shown to 
harbor many different proteinsi,2,8,9,14,20,28,35.47,57,68. Further, because the amyloid 
precursor protein has structural similarities to heparin sulfate proteoglycanses, 
bioctive compounds such as such as transforming growth factor (TGF)6 and 
fibroblast growth factorss have an affinity for it. Interestingly, abherrent sprouting 
occasionally occurs in Alzheimer's disease when neurites enter plaque regionszs. 
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Further, there have been reports of enhanced survival and outgrowth in cultured 
neurons exposed to amyloid4,76,77. An in depth study of amyloid's substrate 
qualities may be important to understanding its role in disease states. 
Also in Paper II, it was shown that amyloid is not inherently toxic to 
hippocampal neurons. Instead, I demonstrated that amyloid became toxic when 
neurons were serum deprived. Comparable results have also been seen in both 
human and rat cortical cultures. Two independent groups37.46 exposed neurons to 
amyloid, but did not observe toxicity. Toxicity was only induced after amyloid 
exposed neurons were stressed by normally subtoxic levels of glutamate. 
Mattson and colleagues46, further demonstrated that amyloid disrupts calcium 
homeostasis. It was suggested that this disruption enhances toxicity in response 
to glutamate. 
In my studies, I did not examine changes in calcium homeostasis, but I did 
find that oxidative stress is involved in amyloid toxicity. Because free radicals are 
known to attack membrane lipids, amyloid exposure may challenge membrane 
integrity perhaps disrupting calcium homeostasis. At present, though, I have no 
clues as to the relationship between amyloid and oxidative stress. Follow-up 
studies should examine whether amyloid itself is subject to free radical attack, as 
well as the involvement of glutathione and superoxide dismutase. In Alzheimer's 
patients there is some evidence that glutathione and superoxide dismutase levels 
are lowered, although these studies were complicated by malnutritionso. 
To summarize, my work has shown that cultured hippocampal neurons are 
responsive to the bioactive compounds, aluminum and amyloid. Both were 
presented to neurons by unconventional means in order to more closely mimic the 
in vivo environment. It is hoped that these studies will serve as the basis for 
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future work examining the mechanisms that are involved with each compound. 
Answers to these questions should help to unravel the etiology and provide 
effective treatments for debilitating neurodegenerative diseases like Alzheimer's 
Disease. 
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P1-28 
pi-40 
P25-35 
pA4 
PAP 
pAPP 
AD 
AL 
BSA 
cAMP 
DMSO 
El 7-18 
EAA 
PBS 
HRP 
IR 
MAP-2 
MEM 
NFT 
NO 
PBS 
APPENDIX 
ABBREVIATIONS USED THROUGHOUT THIS TEXT 
amino acids 1-28 of the beta amyloid protein 
amino acids 1-40 of the beta amyloid protein 
amino acids 25-35 of the beta amyloid protein 
beta amyloid protein 
beta amyloid protein 
beta amyloid precursor protein 
Alzheimer's disease 
aluminum 
bovine serum albumin 
cyclic adenosine monophosphate 
dimethyl sulfoxide 
embryonic day 17 to 18 
excitatory amino acid 
fetal bovine serum 
horse radish peroxidase 
immunoreactivity 
microtubule associated protein - 2 
minimum essential medium 
neurofibrillary tangle 
nitric oxide 
phosphate buffered saline 
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PEI polyethylenimine 
SEM scanning electron microscopy 
TF transferrin 
TF-AL complexed transferrin and aluminum 
